Form 4: Fennec Pharmaceuticals CFO Reports Share Activity
SEC Form 4 Filing
Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition and disposal of common shares related to the release of restricted stock.
Summary
- Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, reported a transaction involving the company's common shares on May 16, 2025.
- Andrade acquired 16,667 common shares at a price of $0.
- Following this transaction, Andrade disposed of an unspecified amount of shares, resulting in a total of 150,300 shares beneficially owned.
- The transaction is related to the release of restricted shares awarded on May 16, 2024.
Sentiment
Score: 5
Explanation: This is a neutral report on share transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and share ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it primarily reflects internal compensation adjustments.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date of original share award. |
| 05/16/2025 | Date of transaction: acquisition and disposal of shares. |
| 05/19/2025 | Date of signature on the report. |
Keywords
Fennec Pharmaceuticals, Robert Andrade, CFO, Form 4, Beneficial Ownership, Common Shares, Restricted Stock, FENC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.